Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF.

Clin Cancer Res. 2018 Jun 28. pii: clincanres.0531.2018. doi: 10.1158/1078-0432.CCR-18-0531. [Epub ahead of print]

PMID:
29954777
2.

A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.

Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH.

Cancers (Basel). 2018 May 14;10(5). pii: E142. doi: 10.3390/cancers10050142. Review.

3.

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.

Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E 3rd, Brody JR.

Oncotarget. 2016 Nov 8;8(48):83446-83456. doi: 10.18632/oncotarget.13225. eCollection 2017 Oct 13.

4.

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM.

Cancer Biol Ther. 2018 Apr 3;19(4):249-253. doi: 10.1080/15384047.2016.1210743. Epub 2018 Mar 6.

PMID:
27466707
5.

Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review.

Rahib L, Fleshman JM, Matrisian LM, Berlin JD.

JAMA Oncol. 2016 Sep 1;2(9):1209-16. doi: 10.1001/jamaoncol.2016.0585. Review.

PMID:
27270617
6.

The Past, Present, and Future of Pancreatic Cancer Clinical Trials.

Matrisian LM, Berlin JD.

Am Soc Clin Oncol Educ Book. 2016;35:e205-15. doi: 10.14694/EDBK_159117. Review.

7.

Myeloid-specific TGF-β signaling in bone promotes basic-FGF and breast cancer bone metastasis.

Meng X, Vander Ark A, Lee P, Hostetter G, Bhowmick NA, Matrisian LM, Williams BO, Miranti CK, Li X.

Oncogene. 2016 May 5;35(18):2370-8. doi: 10.1038/onc.2015.297. Epub 2015 Aug 17.

PMID:
26279296
8.

New tools for the quantitative assessment of prodrug delivery and neurotoxicity.

Samuelson LE, Scherer RL, VanSaun MN, Fan KH, Dozier EA, Carter KJ, Koyama T, Shyr Y, Aschner M, Stanwood GD, Bornhop DJ, Matrisian LM, McIntyre JO.

Neurotoxicology. 2015 Mar;47:88-98. doi: 10.1016/j.neuro.2015.02.005. Epub 2015 Feb 27.

9.

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM.

Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155. Erratum in: Cancer Res. 2014 Jul 15;74(14):4006.

10.

Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease.

Seeley EH, Wilson KJ, Yankeelov TE, Johnson RW, Gore JC, Caprioli RM, Matrisian LM, Sterling JA.

Bone. 2014 Apr;61:208-16. doi: 10.1016/j.bone.2014.01.017. Epub 2014 Jan 30.

11.

Pancreatic cancer clinical trials and accrual in the United States.

Hoos WA, James PM, Rahib L, Talley AW, Fleshman JM, Matrisian LM.

J Clin Oncol. 2013 Sep 20;31(27):3432-8. doi: 10.1200/JCO.2013.49.4823. Epub 2013 Aug 19.

PMID:
23960185
12.

Synthesis and in vitro efficacy of MMP9-activated NanoDendrons.

Samuelson LE, Scherer RL, Matrisian LM, McIntyre JO, Bornhop DJ.

Mol Pharm. 2013 Aug 5;10(8):3164-74. doi: 10.1021/mp4002206. Epub 2013 Jun 24.

13.

Increased metastases are associated with inflammation and matrix metalloproteinase-9 activity at incision sites in a murine model of peritoneal dissemination of colorectal cancer.

Lee IK, Vansaun MN, Shim JH, Matrisian LM, Gorden DL.

J Surg Res. 2013 Apr;180(2):252-9. doi: 10.1016/j.jss.2012.04.074. Epub 2012 May 18.

PMID:
22763216
14.

Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA.

Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30.

15.

An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC.

PLoS One. 2012;7(1):e29862. doi: 10.1371/journal.pone.0029862. Epub 2012 Jan 4.

16.

Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.

Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR.

PLoS One. 2011;6(11):e27090. doi: 10.1371/journal.pone.0027090. Epub 2011 Nov 11.

17.

Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.

Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, Matrisian LM, Brown HA.

PLoS One. 2011;6(8):e22775. doi: 10.1371/journal.pone.0022775. Epub 2011 Aug 9.

18.

TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.

Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA.

Cancer Res. 2011 Feb 1;71(3):822-31. doi: 10.1158/0008-5472.CAN-10-2993. Epub 2010 Dec 28.

19.

MMP-2 contributes to the development of the mouse ventral prostate by impacting epithelial growth and morphogenesis.

Bruni-Cardoso A, Lynch CC, Rosa-Ribeiro R, Matrisian LM, Carvalho HF.

Dev Dyn. 2010 Sep;239(9):2386-92. doi: 10.1002/dvdy.22382.

20.

Rapid extravasation and establishment of breast cancer micrometastases in the liver microenvironment.

Martin MD, Kremers GJ, Short KW, Rocheleau JV, Xu L, Piston DW, Matrisian LM, Gorden DL.

Mol Cancer Res. 2010 Oct;8(10):1319-27. doi: 10.1158/1541-7786.MCR-09-0551. Epub 2010 Aug 19.

21.

Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA.

Lynch CC, Vargo-Gogola T, Matrisian LM, Fingleton B.

J Oncol. 2010;2010:530745. doi: 10.1155/2010/530745. Epub 2010 Jun 10.

22.

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ.

Cancer Res. 2010 May 1;70(9):3618-27. doi: 10.1158/0008-5472.CAN-09-2664.

23.

Near-infrared optical proteolytic beacons for in vivo imaging of matrix metalloproteinase activity.

McIntyre JO, Scherer RL, Matrisian LM.

Methods Mol Biol. 2010;622:279-304. doi: 10.1007/978-1-60327-299-5_18.

24.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM.

Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.

25.

Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.

Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, Matrisian LM, Lynch CC.

Cancer Res. 2009 Aug 15;69(16):6747-55. doi: 10.1158/0008-5472.CAN-08-3949.

26.

An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.

Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR.

Clin Cancer Res. 2009 Jul 15;15:4529. No abstract available.

27.

Optical proteolytic beacons for in vivo detection of matrix metalloproteinase activity.

McIntyre JO, Matrisian LM.

Methods Mol Biol. 2009;539:155-74. doi: 10.1007/978-1-60327-003-8_9.

PMID:
19377965
28.

Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse.

Sinnamon MJ, Carter KJ, Fingleton B, Matrisian LM.

Int J Exp Pathol. 2008 Dec;89(6):466-75. doi: 10.1111/j.1365-2613.2008.00621.x.

29.

Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon.

Scherer RL, VanSaun MN, McIntyre JO, Matrisian LM.

Mol Imaging. 2008 May-Jun;7(3):118-31.

30.

Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment.

McCawley LJ, Wright J, LaFleur BJ, Crawford HC, Matrisian LM.

Am J Pathol. 2008 Nov;173(5):1528-39. doi: 10.2353/ajpath.2008.080132. Epub 2008 Oct 2.

31.

The Translational Research Working Group developmental pathway for interventive devices.

Dorfman GS, Lawrence TS, Matrisian LM; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5700-6. doi: 10.1158/1078-0432.CCR-08-1263.

32.

The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).

Schilsky RL, Gordon G, Gilmer TM, Courtneidge SA, Matrisian LM, Grad O, Nelson WG; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5685-91. doi: 10.1158/1078-0432.CCR-08-1265.

33.

The Translational Research Working Group developmental pathway for image-based assessment modalities.

Dorfman GS, Sullivan DC, Schnall MD, Matrisian LM; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5678-84. doi: 10.1158/1078-0432.CCR-08-1264.

34.

Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth.

Martin MD, Fingleton B, Lynch CC, Wells S, McIntyre JO, Piston DW, Matrisian LM.

Clin Exp Metastasis. 2008;25(8):877-85. doi: 10.1007/s10585-008-9206-y. Epub 2008 Sep 12.

35.

Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI.

Quarles CC, Lepage M, Gorden DL, Fingleton B, Yankeelov TE, Price RR, Matrisian LM, Gore JC, McIntyre JO.

Magn Reson Med. 2008 Sep;60(3):718-26. doi: 10.1002/mrm.21724.

36.

Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B.

Cancer Res. 2008 Aug 1;68(15):6251-9. doi: 10.1158/0008-5472.CAN-08-0537.

37.

Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.

Macias-Perez I, Borza C, Chen X, Yan X, Ibanez R, Mernaugh G, Matrisian LM, Zent R, Pozzi A.

Cancer Res. 2008 Aug 1;68(15):6127-35. doi: 10.1158/0008-5472.CAN-08-1395.

38.

The Translational Research Working Group developmental pathways: introduction and overview.

Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, Viner J, Hautala J, Grad O; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5664-71. doi: 10.1158/1078-0432.CCR-08-1268. Epub 2008 Jul 8.

39.

Imaging matrix metalloproteinases in cancer.

Scherer RL, McIntyre JO, Matrisian LM.

Cancer Metastasis Rev. 2008 Dec;27(4):679-90. doi: 10.1007/s10555-008-9152-9. Review.

PMID:
18465089
40.

A protective role of mast cells in intestinal tumorigenesis.

Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM.

Carcinogenesis. 2008 Apr;29(4):880-6. doi: 10.1093/carcin/bgn040. Epub 2008 Feb 6.

PMID:
18258601
41.

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.

Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL.

Cancer Cell. 2008 Jan;13(1):23-35. doi: 10.1016/j.ccr.2007.12.004.

42.

Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch.

Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Pépin C, Gore JC, Matrisian LM, McIntyre JO.

Mol Imaging. 2007 Nov-Dec;6(6):393-403.

PMID:
18053410
43.

Emerging roles of proteases in tumour suppression.

López-Otín C, Matrisian LM.

Nat Rev Cancer. 2007 Oct;7(10):800-8. Review.

PMID:
17851543
44.

The other side of MMPs: protective roles in tumor progression.

Martin MD, Matrisian LM.

Cancer Metastasis Rev. 2007 Dec;26(3-4):717-24. Review.

PMID:
17717634
45.

Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor.

Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM.

Cancer Res. 2007 Jul 15;67(14):6760-7.

46.

Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.

Fingleton B, Carter KJ, Matrisian LM.

Cancer Res. 2007 May 15;67(10):4800-6.

47.
48.

Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment.

Schwartz DR, Moin K, Yao B, Matrisian LM, Coussens LM, Bugge TH, Fingleton B, Acuff HB, Sinnamon M, Nassar H, Platts AE, Krawetz SA, Linebaugh BE, Sloane BF.

Mol Cancer Res. 2007 May;5(5):443-54.

49.

Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment.

Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM.

Int J Cancer. 2007 Aug 1;121(3):495-500.

50.

Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction.

Nicoud IB, Jones CM, Pierce JM, Earl TM, Matrisian LM, Chari RS, Gorden DL.

Cancer Res. 2007 Mar 15;67(6):2720-8.

Supplemental Content

Loading ...
Support Center